Hoʻolālā ʻia ka noiʻi lapaʻau e loiloi i ka palekana a me ka maikaʻi o LNK01001 i nā kumuhana me ka maʻi o ka rheumatoid maʻemaʻe a i ʻole koʻikoʻi ka pane maikaʻi ʻole me ka intolerance i nā lāʻau antirheumatic synthetic maʻi-modifying antirheumatic (csDMARDs).
ʻO LNK01001 ka lāʻau lapaʻau hou mua i hoʻomohala ʻia e Lynk Pharmaceuticals, a he mea koho kinase inhibitor no ka mālama ʻana i nā maʻi autoimmune. Ma mua, ua hoʻopau ʻo LNK01001 i nā haʻawina lapaʻau Phase I i nā kumuhana olakino i ke kauwela o kēia makahiki ma Kina a ma Australia a me Iapana, kākoʻo ʻia e Lynk Pharmaceuticals a me kāna hoa US, kēlā me kēia. Ua hōʻike nā hopena i ka palekana o ka lāʻau lapaʻau a ʻae maikaʻi ʻia. Eia kekahi, ua ʻae ʻia ʻo LNK01001 e ka National Medical Products Administration of China (NMPA) no ka loiloi loiloi o nā hōʻailona hou - ankylosing spondylitis (AS) a me atopic dermatitis (AD).
ʻO Professor Xiaofeng Zeng ka mea noiʻi nui o kēia noiʻi a me ka luna o ka 'Oihana Rheumatology a me Immunology o Peking Union Medical College Hospital a me Chinese Academy of Medical Sciences.
He aha e lawe ʻia mai kēia ʻatikala:
- Ma mua, ua hoʻopau ʻo LNK01001 i nā haʻawina lapaʻau Phase I i nā kumuhana olakino i ke kauwela o kēia makahiki ma Kina a ma Australia a me Iapana, kākoʻo ʻia e Lynk Pharmaceuticals a me kāna hoa US, kēlā me kēia.
- ʻO Professor Xiaofeng Zeng ka mea noiʻi nui o kēia noiʻi a me ka luna o ka 'Oihana Rheumatology a me Immunology o Peking Union Medical College Hospital a me Chinese Academy of Medical Sciences.
- Hoʻolālā ʻia ka noiʻi lapaʻau e loiloi i ka palekana a me ka maikaʻi o LNK01001 i nā kumuhana me ka maʻi o ka rheumatoid maʻemaʻe a i ʻole koʻikoʻi ka pane maikaʻi ʻole me ka intolerance i nā lāʻau antirheumatic synthetic maʻi-modifying antirheumatic (csDMARDs).
